NexImmune, Inc. (NEXI) DCF Valuation
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
NexImmune, Inc. (NEXI) Bundle
Evaluate NexImmune, Inc.'s (NEXI) financial outlook like an expert! This (NEXI) DCF Calculator comes with pre-filled financials and offers you the flexibility to modify revenue growth, WACC, margins, and other essential assumptions to align with your projections.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITDA | -20.4 | -27.1 | -52.4 | -61.6 | -28.2 | .0 | .0 | .0 | .0 | .0 |
EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Depreciation | .4 | .6 | .9 | 1.5 | 1.0 | .0 | .0 | .0 | .0 | .0 |
Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
EBIT | -20.9 | -27.7 | -53.3 | -63.1 | -29.2 | .0 | .0 | .0 | .0 | .0 |
EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Total Cash | 10.1 | 5.0 | 81.8 | 34.6 | 4.6 | .0 | .0 | .0 | .0 | .0 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .0 | .0 | .0 | .1 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Inventories | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Accounts Payable | 1.2 | 2.8 | 1.0 | 2.4 | 1.3 | .0 | .0 | .0 | .0 | .0 |
Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Capital Expenditure | -1.2 | -.9 | -2.4 | -1.3 | .0 | .0 | .0 | .0 | .0 | .0 |
Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITAT | -20.6 | -29.4 | -54.1 | 518.9 | -29.2 | .0 | .0 | .0 | .0 | .0 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -20.3 | -28.0 | -57.3 | 520.4 | -29.2 | -1.3 | .0 | .0 | .0 | .0 |
WACC, % | 10.52 | 10.53 | 10.53 | 9.47 | 10.53 | 10.31 | 10.31 | 10.31 | 10.31 | 10.31 |
PV UFCF | ||||||||||
SUM PV UFCF | -1.2 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 0 | |||||||||
Terminal Value | 0 | |||||||||
Present Terminal Value | 0 | |||||||||
Enterprise Value | -1 | |||||||||
Net Debt | -3 | |||||||||
Equity Value | 2 | |||||||||
Diluted Shares Outstanding, MM | 1 | |||||||||
Equity Value Per Share | 1.83 |
What You Will Get
- Comprehensive NEXI Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Real-Time Calculations: Intrinsic value and NPV are computed automatically.
- Scenario Analysis: Evaluate various scenarios to assess NexImmune’s future prospects.
- User-Friendly Design: Designed for industry professionals yet easy to navigate for newcomers.
Key Features
- 🔍 Real-Life NEXI Financials: Pre-filled historical and projected data for NexImmune, Inc. (NEXI).
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate NexImmune’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize NexImmune’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review NexImmune’s pre-filled financial data and forecasts.
- Step 3: Modify key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you adjust your assumptions.
- Step 5: Evaluate the outputs and leverage the results for your investment strategies.
Why Choose This Calculator for NexImmune, Inc. (NEXI)?
- All-in-One Solution: Combines DCF, WACC, and financial ratio analyses tailored for NexImmune.
- Flexible Inputs: Modify yellow-highlighted fields to explore different financial scenarios.
- In-Depth Analysis: Automatically computes NexImmune’s intrinsic value and Net Present Value.
- Preloaded Information: Historical and projected data provide reliable starting points for analysis.
- Expert-Level Tool: Perfect for financial analysts, investors, and business consultants focusing on biotech.
Who Should Use This Product?
- Individual Investors: Gain insights to make informed decisions about purchasing or selling NexImmune, Inc. (NEXI) stock.
- Financial Analysts: Enhance valuation methodologies with comprehensive financial models tailored for NexImmune, Inc. (NEXI).
- Consultants: Provide clients with accurate and timely valuation analyses related to NexImmune, Inc. (NEXI).
- Business Owners: Learn how biopharmaceutical companies like NexImmune, Inc. (NEXI) are valued to inform your own business strategies.
- Finance Students: Explore valuation principles using case studies and data from NexImmune, Inc. (NEXI).
What the NexImmune Template Contains
- Comprehensive DCF Model: Editable template featuring detailed valuation calculations specific to NexImmune.
- Real-World Data: NexImmune’s historical and projected financials preloaded for thorough analysis.
- Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into performance.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics relevant to NexImmune.
- Dashboard with Visual Outputs: Charts and tables designed for clear, actionable results tailored to NexImmune's data.